Efficacy of Madhav Rasayan Plus as adjuvant in moderate COVID-19 patients: Preliminary outcomes of randomized controlled trial

Apart from all the gloominess, the COVID-19 Pandemic has a silver lining of bringing a renaissance as Ayurveda and integrated medicine are becoming a choice for acute as well as infective diseases. Here we report outcomes of a preliminary work, the randomized controlled trial (CTRI/2021/02/031256) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamadagni, Sameer, Pandkar, Prasad, Saundankar, Tushar, Shirke, Girish, Malekar, Shailesh, Vaidya, V.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127050/
https://www.ncbi.nlm.nih.gov/pubmed/35634544
http://dx.doi.org/10.1016/j.jaim.2022.100590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9127050/
https://www.ncbi.nlm.nih.gov/pubmed/35634544
http://dx.doi.org/10.1016/j.jaim.2022.100590

Ejemplares similares